[{"ID":"35735_75-2021_NCT04061135","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have Parkinson's disease?\nYes, the patient has Parkinson's disease.\n\n#2: Is the patient eligible for DBS surgery based on a multi-disciplinary consensus review?\nYes, the patient is eligible for DBS surgery based on the inclusion criteria.\n\n#3: Is the patient at least 18 years old?\nYes, the patient is at least 18 years old.\n\n#4: Is the patient willing to participate in the paradigms described in the protocol?\nYes, the patient is willing to participate in the study.\n\nTherefore, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9413928356},{"ID":"33493_71-2021_NCT00975013","TOPIC_YEAR":2021,"RESPONSE":"The patient is a morbidly obese woman who is considering laparoscopic Roux-en-Y gastric bypass surgery.\n\nThe clinical trial is investigating changes in bone mineral density and bone metabolism after laparoscopic Roux-en-Y gastric bypass surgery.\n\nTherefore, the patient is eligible for the clinical trial because she meets the inclusion criteria of being a morbidly obese female patient undergoing elective laparoscopic Roux-en-Y gastric bypass surgery.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9541200163},{"ID":"6945_15-2021_NCT03444259","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have a history of open-heart cardiac surgery?\nNo, the patient does not have a history of open-heart cardiac surgery.\n\n#2: Does the patient have any of the listed inclusion criteria?\nNo, the patient does not have any of the listed inclusion criteria.\n\n#3: Does the patient have any of the listed exclusion criteria?\nNo, the patient does not have any of the listed exclusion criteria.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9370752828},{"ID":"14020_30-2021_NCT01471288","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have hypothyroidism?\nYes, the patient has hypothyroidism, as indicated by her symptoms and laboratory results.\n\n#2: Is the patient under treatment with levothyroxine?\nYes, the patient is under treatment with levothyroxine, as indicated in the patient note.\n\n#3: Does the patient have normal euthyroid function?\nNo, the patient does not have normal euthyroid function, as indicated by her high TSH level and low free T4 level.\n\n#4: Does the patient have goiter?\nNo, the patient does not have goiter, as indicated in the patient note.\n\nBased on the above criteria, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9283160628},{"ID":"30668_65-2021_NCT01865292","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have type 1 or type 2 diabetes?\nThe patient has type 1 diabetes.\n\n#2: Does the patient meet the inclusion criteria for type 1 diabetes?\nYes, the patient meets the inclusion criteria for type 1 diabetes:\n\n* Diagnosed with type 1 diabetes mellitus and treated with insulin for at least 12 months prior to screening\n* Body Mass Index (BMI) between 18.0 and 27.0 kg\/m^2 (both inclusive)\n\n#3: Does the patient meet the exclusion criteria for type 2 diabetes?\nNo, the patient does not meet the exclusion criteria for type 2 diabetes:\n\n* Therapy with oral antidiabetic drugs within the past 3 months prior to screening\n\nTherefore, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9616998395},{"ID":"17390_36-2021_NCT04318184","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have DM?\nNo, the patient does not have DM.\n\n#2: Is the patient aged between 18 and 65 years?\nYes, the patient is aged between 18 and 65 years.\n\n#3: Is the patient willing to complete the three-month exercise program?\nNo, the patient is not willing to complete the three-month exercise program.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9328081166},{"ID":"30771_65-2021_NCT02538120","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have diabetes type 1?\nYes, the patient has diabetes type 1, as confirmed by molecular analysis 7 years ago.\n\n#2: Is the patient a match for the control subjects?\nNot specified in the clinical trial criteria.\n\n#3: Does the patient have any exclusion criteria?\nNo, the patient does not have any exclusion criteria.\n\nTherefore, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9172623625},{"ID":"16884_36-2021_NCT00307632","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient meet the age requirement?\nThe patient is 32 years old, which is within the age range of 18-35 years old specified in the inclusion criteria. Therefore, the patient meets the age requirement.\n\n#2: Does the patient meet the body mass index (BMI) requirement?\nThe patient's BMI is 41.54, which is above the upper limit of 30 specified in the inclusion criteria. Therefore, the patient does not meet the BMI requirement.\n\n#3: Does the patient meet the pregnancy and breastfeeding requirement?\nThe patient has not completed her last term pregnancy at least 4 months prior to study admission, and she is currently breastfeeding. Therefore, the patient does not meet the pregnancy and breastfeeding requirement.\n\n#4: Does the patient meet the medication requirement?\nThe patient is not currently using any depot hormone injections or other hepatic enzyme-inducing drugs, and she has not used these medications within 30 days prior to the pre-study visit. Therefore, the patient meets the medication requirement.\n\nBased on the above assessment, the patient is not eligible for the clinical trial.","PROBA":0.9325508166},{"ID":"5491_12-2021_NCT03884426","TOPIC_YEAR":2021,"RESPONSE":"The patient has Marfan's syndrome, which is a genetic disorder that affects the body's connective tissue. The patient also has known severe mitral valve prolapse with regurgitation, which is a common complication of Marfan's syndrome. The patient is prepared to undergo mitral valve repair\/replacement surgery.\n\nThe clinical trial is titled \"Genetic and Phenotypic Characteristics of Mitral Valve Prolapse\" and is looking to phenotypically characterize patients with typical mitral valve prolapse and identify genes involved in MVP. The patient has typical mitral valve prolapse and has a known genetic condition (Marfan's syndrome) that increases the risk of developing MVP. Therefore, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9255929596},{"ID":"35438_75-2021_NCT01429597","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 55-year-old man with Parkinson's disease.\n\nThe clinical trial is for Fabry disease.\n\nFabry disease is a different condition from Parkinson's disease.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nSo, the patient is \"excluded\" from the clinical trial.","PROBA":0.9334958191},{"ID":"35798_75-2021_NCT04591132","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have a clinical diagnosis of parkinsonism and\/or dystonia and\/or tremor?\n\nYes, the patient has a clinical diagnosis of Parkinson's disease, which is a type of parkinsonism.\n\n#2: Is the patient between 18 and 80 years of age?\n\nYes, the patient is 55 years old, which is within the age range of 18 to 80 years.\n\n#3: Is the patient willing and able to provide informed consent?\n\nYes, the patient is alert and cooperative, and is willing to provide informed consent.\n\n#4: Does the patient have any orthopaedic comorbidities affecting gait or posture?\n\nNo, the patient does not have any orthopaedic comorbidities affecting gait or posture.\n\n#5: Does the patient have any cognitive deficits?\n\nNo, the patient does not have any cognitive deficits.\n\nTherefore, based on the criteria for the clinical trial, the patient is eligible to participate.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9494579512},{"ID":"6715_15-2021_NCT01474564","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have pancreatic adenocarcinoma?\nYes, the patient has a histological diagnosis of pancreatic adenocarcinoma.\n\n#2: Is the patient eligible for chemotherapy treatment?\nYes, the patient is eligible for chemotherapy treatment.\n\n#3: Has the patient had prior surgery, chemotherapy, and\/or radiation therapy for pancreatic adenocarcinoma?\nYes, the patient has had prior surgery (angioplasty) and chemotherapy for pancreatic adenocarcinoma.\n\n#4: What is the patient's ECOG performance status?\nThe patient's ECOG performance status is 2.\n\n#5: Is the patient at least 18 years old?\nYes, the patient is at least 18 years old.\n\nBased on the criteria, the patient is eligible for the clinical trial.","PROBA":0.9542999183},{"ID":"14186_30-2021_NCT03529630","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have inverted nipples?\nNo, the patient does not have inverted nipples. The patient has Hashimoto's thyroiditis, which is an autoimmune disease that affects the thyroid gland.\n\n#2: Is the patient pregnant?\nNo, the patient is not pregnant.\n\n#3: Does the patient have any medical conditions that could interfere with breastfeeding?\nNo, the patient does not have any medical conditions that could interfere with breastfeeding.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9418142024},{"ID":"17051_36-2021_NCT01665547","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have PCOS?\nYes, the patient has PCOS, as indicated by the Rotterdam criteria.\n\n#2: Has the patient received five unsuccessful clomiphene citrate-timed intercourse stimulation cycles?\nNo, the patient has not received any clomiphene citrate-timed intercourse stimulation cycles.\n\n#3: Is the patient younger than 35 years old?\nYes, the patient is younger than 35 years old.\n\nBased on the criteria, the patient is eligible for the clinical trial.","PROBA":0.9153407279},{"ID":"35347_75-2021_NCT00494689","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 55-year-old man with Parkinson's disease, which is a neurodegenerative disorder that affects movement. The clinical trial is focused on gait apraxia due to normal pressure hydrocephalus and cerebral ischemia. Parkinson's disease is not listed as an inclusion criterion for the clinical trial.\n\nTherefore, based on the information provided, the patient would not be eligible for the clinical trial.\n\nSo, the patient is \"excluded\" from the clinical trial.","PROBA":0.9226059578},{"ID":"33418_71-2021_NCT00402077","TOPIC_YEAR":2021,"RESPONSE":"#1: Check if the patient meets the inclusion criteria.\n\nThe patient is obese with a BMI of 41.54, which meets the inclusion criterion of a BMI >=30 kg\/m^2 to <=50 kg\/m^2.\n\n#2: Check if the patient has any exclusion criteria.\n\nThe patient has not had any previous surgical or medical treatments for weight loss, and has not used any investigational drugs within the past year. She is also not currently enrolled in or planning to enroll in a formal weight-loss program. Therefore, the patient does not have any exclusion criteria.\n\nBased on the above, the patient is eligible for the clinical trial.","PROBA":0.8907423382},{"ID":"17355_36-2021_NCT04116905","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have metabolic syndrome?\nYes, the patient has metabolic syndrome, as she meets at least 3 of the following 5 criteria:\n\n* Waist circumference \u226585 cm (male) or 80 cm (female)\n* TG \u2265150 mg\/dL or with lipid-lowering treatment\n* HDL<40 mg\/dL (male) \/50 mg\/dL (female)\n* SBP \u2265 130 mmHg and \/ or DBP \u2265 85 mmHg and \/ or with diagnosed hypertension and anti-hypertensive treatment\n* fasting glucose \u2265 5.6 mmol\/L and \/ or with diagnosed type 2 diabetes and hypoglycemic treatment\n\n#2: Is the patient obese?\nYes, the patient is obese, as her BMI is 41.54.\n\n#3: Is the patient Han Chinese?\nYes, the patient is Han Chinese.\n\n#4: Is the patient willing to participate?\nYes, the patient is willing to participate.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9642653391},{"ID":"28043_40-2022_NCT04290013","TOPIC_YEAR":2022,"RESPONSE":"#1: Age\nThe patient is 23 years old, which is within the age range of 35-49 years old specified in the inclusion criteria. Therefore, the patient meets the age requirement.\n\n#2: Normal gynecologic and breast examination\nThe patient has a normal gynecologic and breast examination, which is an inclusion criterion.\n\n#3: Heavy periods\nThe patient has heavy periods, which is an inclusion criterion.\n\n#4: Normal ultrasound, hysteroscopy, and endometrial biopsy\nThe patient has normal ultrasound, hysteroscopy, and endometrial biopsy results, which are inclusion criteria.\n\n#5: No contraindication to tranexamic acid or Norethisterone acetate\nThe patient does not have any contraindications to tranexamic acid or Norethisterone acetate, which is an inclusion criterion.\n\nTherefore, based on the criteria specified in the clinical trial, the patient is eligible to participate.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9371233812},{"ID":"27525_40-2022_NCT00617721","TOPIC_YEAR":2022,"RESPONSE":"#1: Does the patient have unexplained provoked hemorrhages?\nYes, the patient has prolonged oral bleeding after a tooth extraction, which is an example of an unexplained provoked hemorrhage.\n\n#2: Is the patient's bleeding associated with reduced prothrombin consumption?\nThe patient's bleeding is associated with a low prothrombin consumption, as the patient's residual prothrombin in serum is > 5%.\n\n#3: Is the patient a family member of someone with an unexplained hemorrhage?\nNo, the patient is not a family member of someone with an unexplained hemorrhage.\n\n#4: Does the patient have any other medical problems or conditions that could explain the bleeding disorder?\nNo, the patient does not have any other medical problems or conditions that could explain the bleeding disorder.\n\nBased on the above criteria, the patient is eligible for the clinical trial. Therefore, the answer is:\n\nA: Eligible","PROBA":0.9145472624},{"ID":"5349_12-2021_NCT02033811","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have severe mitral regurgitation?\nYes, the patient has severe mitral regurgitation.\n\n#2: Is the patient undergoing percutaneous mitral valve repair (PMVR) with the MitraClip\u00ae system?\nNo, the patient is not undergoing PMVR with the MitraClip\u00ae system.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nSo, the patient is \"excluded\" from the clinical trial.","PROBA":0.9317331226},{"ID":"27831_40-2022_NCT02869074","TOPIC_YEAR":2022,"RESPONSE":"The patient has prolonged oral bleeding after a tooth extraction, which is a common symptom of von Willebrand disease (VWD).\n\nThe patient's laboratory findings show a normal platelet count, but abnormal results in the ristocetin cofactor assay, CB, and FVIII:C. These results are consistent with VWD.\n\nThe patient has a family history of excessive bleeding during menstrual periods, which is also consistent with VWD.\n\nTherefore, based on the patient's symptoms and laboratory findings, it is likely that the patient has VWD and would be eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9093997626},{"ID":"35670_75-2021_NCT03587168","TOPIC_YEAR":2021,"RESPONSE":"#1: Age\nThe patient is 55 years old, which is within the age range of 40-75 years specified in the inclusion criteria. Therefore, the patient meets the age requirement.\n\n#2: Neurologist-diagnosed Parkinson's Disease\nThe patient has been diagnosed with Parkinson's disease by a neurologist, which meets the inclusion criterion.\n\n#3: Hoehn & Yahr (H&Y) stages 1 to 4\nThe patient's disease is ranked as mild, Hoehn-Yahr Stage I, which falls within the range of H&Y stages 1 to 4. Therefore, the patient meets this inclusion criterion.\n\n#4: Able to walk 10 m with or without aids\nThe patient is able to walk 10 m with or without aids, which meets the inclusion criterion.\n\nBased on the above, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9441633427},{"ID":"35400_75-2021_NCT01010802","TOPIC_YEAR":2021,"RESPONSE":"#1: Check if the patient meets the inclusion criteria.\n\nThe patient's Hoehn-Yahr stage is I, which is within the range of the inclusion criteria (I-III).\n\n#2: Check if the patient has a good response to levodopa.\n\nThe patient's motor UPDRS score shows a more than 30% change, which is considered a good response to levodopa.\n\n#3: Check if the patient has an acceptable general health status.\n\nThe patient is alert and cooperative, and there is no mention of any chronic psychiatric or other neurological diseases, so the patient meets the inclusion criteria.\n\nTherefore, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9090023783},{"ID":"17141_36-2021_NCT02450097","TOPIC_YEAR":2021,"RESPONSE":"#1: Age\nThe patient is 32 years old, which is within the inclusion criteria age range of > 18 years of age.\n\n#2: BMI\nThe patient's BMI is 41.54, which is within the inclusion criteria range of BMI 23-37.\n\n#3: No exclusion criteria met\nThe patient does not have any exclusion criteria met, such as BMI below 23, waist circumference 80 cm or less for women and 94 cm or less for men, total fat percent of body weight less than 23%, treatment with insulin and sulfonylurea drugs, chronic kidneys disease (CKD) stage 4 and 5 (eGFR <30 ml\/min), pregnancy and breast-feed, active athletes, or history of eating disorder.\n\nTherefore, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.94572206},{"ID":"33685_71-2021_NCT02510443","TOPIC_YEAR":2021,"RESPONSE":"The patient is a woman who is considering a laparoscopic gastric bypass.\n\nThe clinical trial is an observational study on contraception with Essure in France.\n\nThe patient is not considering Essure as a form of contraception, but rather a laparoscopic gastric bypass.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nSo, the patient is \"excluded\" from the clinical trial.","PROBA":0.9322066907},{"ID":"17244_36-2021_NCT03165812","TOPIC_YEAR":2021,"RESPONSE":"#1: Age\nThe patient is 32 years old, which is within the inclusion criteria age range of 18-65 years.\n\n#2: BMI\nThe patient has a BMI of 41.54, which is above the inclusion criteria range of 23.5-30 kg\/m2.\n\n#3: Diabetes duration\nThe patient has had diabetes for more than two years, which meets the inclusion criteria.\n\n#4: ASA classification\nThe patient's ASA classification is not specified, but it is not excluded by the criteria.\n\n#5: Other exclusions\nThe patient does not have any of the excluded conditions, such as psychiatric disorders or logistic issues.\n\nBased on the criteria, the patient is eligible for the clinical trial.","PROBA":0.9177185676},{"ID":"6832_15-2021_NCT02426944","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 70-year-old woman with a history of coronary artery disease, atrial fibrillation, and chronic kidney disease. She has been treated with anticoagulation therapy in the past.\n\nThe clinical trial is investigating the use of left atrial appendage closure vs. novel anticoagulation agents in patients with atrial fibrillation.\n\nBased on the patient's history of atrial fibrillation and previous anticoagulation therapy, she would likely meet the inclusion criteria for the clinical trial. However, there are some exclusion criteria that may apply:\n\n* The patient has a history of significant bleeding, which may exclude her from the trial.\n* The patient has chronic kidney disease, which may be a contraindication for the trial.\n\nTherefore, it is uncertain whether the patient would be eligible for the clinical trial without further information about the specific criteria and the patient's current medical status.","PROBA":0.9074327712},{"ID":"6905_15-2021_NCT03081663","TOPIC_YEAR":2021,"RESPONSE":"#1: Patients requiring primary total knee replacement\n\nThe patient is not eligible for this clinical trial because the patient has a history of CAD and pancreatic adenocarcinoma, and the trial is only for patients who require primary total knee replacement.\n\n#2: Patients willing and able to comply with follow-up requirements and self-evaluations\n\nThe patient is not eligible for this clinical trial because the patient has a history of CAD and pancreatic adenocarcinoma, and the trial is only for patients who are willing and able to comply with follow-up requirements and self-evaluations.\n\n#3: Patients willing to sign an IRB approved informed consent form\n\nThe patient is not eligible for this clinical trial because the patient has a history of CAD and pancreatic adenocarcinoma, and the trial is only for patients who are willing to sign an IRB approved informed consent form.\n\n#4: English fluency (printed instructions are provided in English only)\n\nThe patient is not eligible for this clinical trial because the patient has a history of CAD and pancreatic adenocarcinoma, and the trial is only for patients who are fluent in English.\n\n#5: Varus arthropathy\n\nThe patient is not eligible for this clinical trial because the patient has a history of CAD and pancreatic adenocarcinoma, and the trial is only for patients with varus arthropathy.\n\n#6: Osteoarthritis\n\nThe patient is not eligible for this clinical trial because the patient has a history of CAD and pancreatic adenocarcinoma, and the trial is only for patients with osteoarthritis.\n\n#7: ASA less than or equal to 3\n\nThe patient is not eligible for this clinical trial because the patient has a history of CAD and pancreatic adenocarcinoma, and the trial is only for patients with an ASA score of less than or equal to 3.\n\n#8: Home\/cell phone access\n\nThe patient is not eligible for this clinical trial because the patient has a history of CAD and pancreatic adenocarcinoma, and the trial is only for patients with home\/cell phone access.\n\n#9: Adult to accompany patient home post-operatively and to stay with patient for a minimum period of 1-2 days\n\nThe patient is not eligible for this clinical trial because the patient has a history of CAD and pancreatic adenocarcinoma, and the trial is only for patients who have an adult to accompany them home post-operatively and to stay with them for a minimum period of 1-2 days.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9794900587},{"ID":"5402_12-2021_NCT02722551","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient meet the inclusion criteria?\n\nYes, the patient meets the inclusion criteria of moderate\/severe or severe mitral regurgitation, as indicated by the echocardiogram with an EF of 65%.\n\n#2: Does the patient meet the exclusion criteria?\n\nNo, the patient does not meet any of the exclusion criteria.\n\nTherefore, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9011053374},{"ID":"14264_30-2021_NCT04364087","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have polycystic ovary syndrome (PCOS)?\nNo, the patient does not have PCOS. The patient has Hashimoto's thyroiditis.\n\n#2: Is the patient Vietnamese?\nNo, the patient is not Vietnamese.\n\n#3: Is the patient infertile?\nNo, the patient is not infertile.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nSo, the patient is \"excluded\" from the clinical trial.","PROBA":0.9365028012},{"ID":"17364_36-2021_NCT04184622","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have a BMI \u226530 kg\/m\u00b2?\nYes, the patient has a BMI of 41.54, which is greater than or equal to 30 kg\/m\u00b2.\n\n#2: Does the patient have a history of at least one unsuccessful dietary effort to lose body weight?\nYes, the patient has tried diets and exercise to lose weight in the past.\n\n#3: Does the patient have any of the exclusion criteria?\nNo, the patient does not have any of the exclusion criteria.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9337807445},{"ID":"16976_36-2021_NCT01020279","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have muscle pain induced by eccentric exercise?\nNo, the patient does not have muscle pain induced by eccentric exercise.\n\n#2: Is the patient between 18-55 years old?\nYes, the patient is between 18-55 years old.\n\n#3: Is the patient willing to abstain from any physical therapy, hard physical work, exercise, or sauna during the study observation period?\nNo, the patient is not willing to abstain from physical therapy, hard physical work, exercise, or sauna during the study observation period.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9361026413},{"ID":"17399_36-2021_NCT04397055","TOPIC_YEAR":2021,"RESPONSE":"#1: Age\nThe patient is 32 years old, which is within the inclusion criteria age range of 30-75 years old.\n\n#2: BMI\nThe patient's BMI is 41.54, which is within the inclusion criteria range of 18.5-39.9 kg\/m2.\n\n#3: Cholesterol levels\nThe patient's total cholesterol level is 180 mg\/dL, which is within the inclusion criteria range of 180-239 mg\/dL.\n\n#4: Triglycerides\nThe patient's triglyceride level is 150 mg\/dL, which is within the inclusion criteria range of 130-199 mg\/dL.\n\n#5: Other health markers\nThe patient does not have any exclusion criteria such as familial hypercholesterolemia, LDL levels greater than the 95th percentile, HDL levels lower than the 20th percentile, or any other chronic or metabolic diseases.\n\nBased on the above criteria, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.949444788},{"ID":"6651_15-2021_NCT00895089","TOPIC_YEAR":2021,"RESPONSE":"The patient is not eligible for the clinical trial. The trial is focused on primary pyogenic liver abscess, and the patient has a history of pancreatic adenocarcinoma, which is not related to the liver. Additionally, the patient has a history of coronary artery disease, mitral valve prolapse, atrial fibrillation, hyperlipemia, hypertension, chronic kidney disease, hypothyroidism, and anemia, which are not included in the inclusion criteria for the trial. Therefore, the patient is not eligible for the clinical trial.\n\nSo, the patient is \"not eligible\" for the clinical trial.","PROBA":0.9312001616},{"ID":"17352_36-2021_NCT04103528","TOPIC_YEAR":2021,"RESPONSE":"#1: Age\nThe patient is 32 years old, which is within the age range of 18-60 years old for the clinical trial. Therefore, the patient meets the inclusion criterion for age.\n\n#2: BMI\nThe patient's BMI is 41.54, which is within the range of 18.5-28 kg\/m^2. Therefore, the patient meets the inclusion criterion for BMI.\n\n#3: Procedure\nThe patient is undergoing a laparoscopic hysteromyoma procedure, which is within the scope of the clinical trial. Therefore, the patient meets the inclusion criterion for procedure.\n\n#4: Other\nThe patient does not have any of the exclusion criteria, such as combining with ovarian disease or ovarian surgery, preoperative Athens Insomnia Scale (AIS) score \u2265 4 points, chronic use of sedative, hypnotic, psychotropic drugs, recent night shift, cross-time zone, irregular life routine, suffering from mental illness or hearing, visual impairment, and existing sleep apnea syndrome. Therefore, the patient is eligible for the clinical trial.\n\nSo, the patient is eligible for the clinical trial.","PROBA":0.9474342956},{"ID":"33457_71-2021_NCT00671983","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have a BMI of 41.5 or higher?\nYes, the patient has a BMI of 41.54, which meets the inclusion criteria.\n\n#2: Is the patient scheduled for Laparoscopic roux-en-Y gastric bypass (RYGB) surgery?\nYes, the patient is considering a laparoscopic gastric bypass.\n\n#3: Does the patient have a confirmed diagnosis of OSA?\nNo, the patient does not have a confirmed diagnosis of OSA.\n\n#4: Does the patient have comprehension of spoken and written English?\nYes, the patient has comprehension of spoken and written English.\n\n#5: Does the patient have any exclusion criteria?\nNo, the patient does not have any exclusion criteria.\n\nBased on the above, the patient is eligible for the clinical trial.","PROBA":0.9296637305},{"ID":"33893_71-2021_NCT04175964","TOPIC_YEAR":2021,"RESPONSE":"#1: Age\nThe patient is 34 years old, which is within the age range of 16-35 years for the clinical trial. Therefore, the patient meets the age inclusion criterion.\n\n#2: BMI\nThe patient has a BMI of 41.54, which is greater than or equal to 27, the lower limit of the BMI inclusion criterion. Therefore, the patient meets the BMI inclusion criterion.\n\n#3: PCOS diagnosis\nThe patient has been diagnosed with PCOS based on the Rotterdam criteria, which includes oligo\/anovulation, hyperandrogenism, and polycystic ovaries on ultrasound. Therefore, the patient meets the PCOS diagnosis inclusion criterion.\n\n#4: Other medical conditions\nThe patient does not have any major medical disorders or other concurrent medical illnesses that would exclude her from the clinical trial. Therefore, the patient meets the exclusion criterion.\n\n#5: Medication use\nThe patient does not currently use any hormonal, anti-diabetic, or anti-obesity drugs, or other drugs that affect hormone levels, carbohydrate metabolism, or appetite. Therefore, the patient meets the exclusion criterion.\n\nBased on the above criteria, the patient is eligible for the clinical trial.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9440792173},{"ID":"17409_36-2021_NCT04548102","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have a history of high-risk pregnancy?\nNo, the patient is not pregnant and does not have a history of high-risk pregnancy.\n\n#2: Is the patient currently pregnant?\nNo, the patient is not pregnant.\n\n#3: Does the patient meet any of the inclusion criteria?\nNo, the patient does not meet any of the inclusion criteria for the clinical trial.\n\n#4: Does the patient meet any of the exclusion criteria?\nNo, the patient does not meet any of the exclusion criteria for the clinical trial.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9430239998},{"ID":"35401_75-2021_NCT01019343","TOPIC_YEAR":2021,"RESPONSE":"#1: Check if the patient has Parkinson's disease.\nYes, the patient has Parkinson's disease.\n\n#2: Check if the patient is over 18 years old.\nYes, the patient is over 18 years old.\n\n#3: Check if the patient is able to give informed consent.\nYes, the patient is able to give informed consent.\n\n#4: Check if the patient has any exclusion criteria.\nNo, the patient does not have any exclusion criteria.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9313726736},{"ID":"6706_15-2021_NCT01384721","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have suspected Coronary Artery Disease (CAD)?\nYes, the patient has a history of Coronary Artery Disease (CAD) and recently underwent a CT scan with findings consistent with pancreatic adenocarcinoma.\n\n#2: Does the patient meet the inclusion criteria for the clinical trial?\nNo, the patient does not meet the inclusion criteria for the clinical trial because the trial is specific to patients with suspected CAD, and the patient has a confirmed diagnosis of pancreatic adenocarcinoma.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9170286476},{"ID":"16905_36-2021_NCT00424658","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have suspected sleep apnea?\nYes, the patient is complaining of sleep apnea and has been diagnosed with sleep apnea.\n\n#2: Is the patient eligible for the clinical trial?\nYes, the patient meets the inclusion criteria for the clinical trial.\n\nSo, the patient is eligible for the clinical trial.\n\n\nA: eligible","PROBA":0.8555331383},{"ID":"33436_71-2021_NCT00502658","TOPIC_YEAR":2021,"RESPONSE":"#1: Age\nThe patient is 34 years old, which is within the age range of 18-65 years old for the clinical trial. Therefore, the patient meets the age inclusion criterion.\n\n#2: BMI\nThe patient has a BMI of 41.5, which is within the range of 25-35 kg\/m2 for the clinical trial. Therefore, the patient meets the BMI inclusion criterion.\n\n#3: Willingness to stop taking any nutritional supplements\nThe patient is willing to stop taking any nutritional supplements, which meets the inclusion criterion.\n\n#4: Exclusion criteria\nThe patient does not have any of the exclusion criteria, such as current smoking, taking prescription medications, experienced at least a 10 pound weight loss over the past 2 months, history of serious heart problems, diagnosed with diabetes, known history of gastrointestinal diseases, undergone surgical procedure for weight loss, history of stroke or seizure activity, medical conditions known to affect serum lipids, history of uncontrolled hypertension or with a current measured blood pressure with diastolic above 90 or systolic above 140 mm Hg, a total serum cholesterol above 240 mg\/dL, known HIV infection, known history of depression and currently taking anti-depression medications, treated for cancer in the last 5 years, known allergies to supplements, or known history of eating disorder.\n\nTherefore, the patient is eligible for the clinical trial.\n\nC: eligible","PROBA":0.9571028078},{"ID":"17218_36-2021_NCT03026933","TOPIC_YEAR":2021,"RESPONSE":"#1: Is the patient's age within the inclusion criteria range of 19-80 years old?\n\nYes, the patient's age is within the inclusion criteria range of 19-80 years old.\n\n#2: Does the patient have high risk for cardiovascular disease according to NCEP APT III?\n\nNo, the patient does not have high risk for cardiovascular disease according to NCEP APT III.\n\n#3: Does the patient have TG levels \u2265130mg\/dL and LDL-C levels \u2265100mg\/dL?\n\nNo, the patient does not have TG levels \u2265130mg\/dL and LDL-C levels \u2265100mg\/dL.\n\n#4: Is the patient taking statins for at least 4 weeks?\n\nNo, the patient is not taking statins.\n\n#5: Does the patient have baseline TG levels \u2265200mg\/dL and LDL-C levels <110mg\/dL?\n\nNo, the patient does not have baseline TG levels \u2265200mg\/dL and LDL-C levels <110mg\/dL.\n\nBased on the criteria, the patient is not eligible for the clinical trial.","PROBA":0.9500872401},{"ID":"17281_36-2021_NCT03422809","TOPIC_YEAR":2021,"RESPONSE":"The patient is a woman, which meets the inclusion criterion of being female.\n\nThe patient's age is within the range of 18 to 44 years old, which meets the inclusion criterion of being between 18 and 44 years old.\n\nThe patient has a regular menstrual cycle, which meets the inclusion criterion of having a regular menstrual cycle.\n\nThe patient's BMI is within the range of 18.5 to 24.9 kg\/m2, which meets the inclusion criterion of having a BMI of 18.5 to 24.9 kg\/m2.\n\nThe patient is not a smoker, which meets the inclusion criterion of not being a smoker.\n\nThe patient is not pregnant, which meets the exclusion criterion of not being pregnant.\n\nThe patient has not had a previous pregnancy within the last 12 months, which meets the exclusion criterion of not having had a previous pregnancy within the last 12 months.\n\nThe patient does not have a known, ongoing health condition\/medical issue that requires regular monitoring by a doctor or regular visits to the hospital, which meets the inclusion criterion of being in general good health.\n\nTherefore, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9632119976},{"ID":"5233_12-2021_NCT00001641","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have a known or suspected inherited connective tissue disorder?\nYes, the patient has a known or suspected inherited connective tissue disorder, specifically Marfan syndrome.\n\n#2: Does the patient have any of the following features in a pattern suggestive of a heritable connective tissue disorder?\nYes, the patient has several features that are consistent with Marfan syndrome, including:\n\n* Marfanoid body habitus\n* Aortic dilatation and\/or dissection\n* Ectopia lentis, detached retina, vitreous degeneration and\/or early onset high myopia\n* Posterior cleft palate\n* Joint laxity and\/or dislocation\n* Premature osteoarthritis\n* Skin fragility, striae, easy bruisability and\/or hyperextensibility\n* Pectus excavatum or carinatum\n* Scoliosis, spondylolisthesis, and\/or dural ectasia\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9606926568},{"ID":"17144_36-2021_NCT02454127","TOPIC_YEAR":2021,"RESPONSE":"#1: Check if the patient meets the inclusion criteria.\n\nThe patient's BMI is 41.54, which is well above the inclusion criteria of 27-42. Therefore, the patient meets the inclusion criteria.\n\n#2: Check if the patient has any exclusion criteria.\n\nThe patient does not have any exclusion criteria, such as age under 18 years, insulin therapy, unstable chronic illness, or unwillingness to follow dietary advice. Therefore, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9220316148},{"ID":"5545_12-2021_NCT04527367","TOPIC_YEAR":2021,"RESPONSE":"The patient has Marfan's syndrome, which is a genetic disorder that affects the body's connective tissue. This disorder can affect various parts of the body, including the heart, blood vessels, and joints.\n\nThe patient has severe mitral valve prolapse with regurgitation, which is a condition where the mitral valve does not close properly and blood leaks back into the heart. This is a common complication of Marfan's syndrome.\n\nThe patient is planned for mitral valve repair\/replacement surgery, which is a surgical procedure to repair or replace the mitral valve.\n\nThe clinical trial is focused on the epidemiology and long-term outcomes of patients with valvular heart disease (VHD).\n\nBased on the information provided, the patient is eligible for the clinical trial because they have a diagnosis of VHD (severe mitral valve prolapse with regurgitation) and are planned for surgical intervention (mitral valve repair\/replacement surgery).\n\nTherefore, the answer is:\n\nA: eligible","PROBA":0.9183239056},{"ID":"35596_75-2021_NCT02895932","TOPIC_YEAR":2021,"RESPONSE":"#1: Age\nThe patient is 55 years old, which is within the age range of 45-80 years old for the clinical trial. Therefore, the patient meets the age inclusion criterion.\n\n#2: Diagnosis\nThe patient has been diagnosed with Parkinson's disease, which is one of the inclusion criteria for the clinical trial.\n\n#3: Other health conditions\nThe patient does not have any of the exclusion criteria, such as a history of stroke, that would preclude them from participating in the clinical trial.\n\nBased on the above, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9107895951},{"ID":"6844_15-2021_NCT02555735","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have pancreatic adenocarcinoma?\nYes, the patient has been diagnosed with pancreatic adenocarcinoma based on the results of EUS with biopsy.\n\n#2: Is the patient treatment-na\u00efve or currently receiving chemotherapy?\nThe patient is currently receiving chemotherapy, so they meet this criterion.\n\n#3: What is the patient's ECOG performance status?\nThe patient's ECOG performance status is 2, which meets the inclusion criterion of ECOG 0-2.\n\n#4: Is the patient hemodynamically stable and\/or physiologically compensated for their anemia?\nThe patient's hemoglobin level is 7.5 g\/dl or greater, indicating that they are hemodynamically stable and\/or physiologically compensated for their anemia.\n\nTherefore, based on the criteria listed in the clinical trial, the patient is eligible for the study.","PROBA":0.9300757597},{"ID":"16999_36-2021_NCT01170390","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 32-year-old obese woman with a BMI of 41.54, which meets the inclusion criterion of BMI > 30kg\/m2.\n\nThe patient is also a high-school teacher and is in good general health, which meets the inclusion criteria of good general health.\n\nThe patient has a normal breast and pelvic exam within the last 9 months, which meets the inclusion criterion of proof of a normal breast and pelvic exam.\n\nThe patient has self-reported normal menstrual periods (24-35 days), which meets the inclusion criterion of self-reported normal menstrual periods.\n\nThe patient's hematocrit is \u2265 36%, which meets the inclusion criterion of hematocrit \u2265 36%.\n\nThe patient's single progesterone level during screening visit is \u2265 3ng\/mL, which meets the inclusion criterion of single progesterone level \u2265 3ng\/mL.\n\nThe patient is not currently pregnant or seeking pregnancy in the next 6 months, which meets the exclusion criterion of currently pregnant\/seeking pregnancy in the next 6 months.\n\nThe patient is not currently breast-feeding, which meets the exclusion criterion of currently breast-feeding.\n\nThe patient does not have a past or current diagnosis of polycystic ovarian disease, which meets the exclusion criterion of past or current diagnosis of polycystic ovarian disease.\n\nThe patient is not currently taking medication that interferes with COC's, which meets the exclusion criterion of currently taking medication that interferes with COC's.\n\nTherefore, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9661576006}]
